Option chain shows key data for ImmuCell's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for ImmuCell.

ImmuCell (NASDAQ:ICCC) Stock, Option Chain

ImmuCell

ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.

PriceSmart

Earnings

News

Pre-Market Outlook

Markets

Trading Ideas

ICCC

KRUS

MANU

PSMT

PriceSmart, Kura Sushi And 3 Stocks To Watch Heading Into Wednesday

Penny Stocks

Small Cap

Movers

ADIL

ASTI

BANL

BDRX

CING

CRKN

CVKD

DTST

ELOX

ENOB

GDTC

HCTI

PIXY

PPBT

PRFX

SILK

VVOS

WLGS

Gainers


	Cadrenal Therapeutics, Inc. (NASDAQ: CVKD) shares surged 131.6% to $4.03 in pre-market trading after gaining 15% on Tuesday.


Why ImmuCell Are Trading Higher; Here Are 20 Stocks Moving Premarket

ANGO

AZTR

MLKN

With U.S. stock futures trading slightly higher this morning on Wednesday, some of the stocks that may grab investor focus today are as follows:

AngioDynamics, Disney And 3 Stocks To Watch Heading Into Wednesday

ImmuCell Corp

Press Releases

ImmuCell Announces Preliminary, Unaudited Sales Results for Q2 2024

ImmuCell to Announce Unaudited Financial Results for the Quarter Ended June 30, 2024

ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2024

ImmuCell Announces Preliminary, Unaudited Sales Results for Q3 2024

ImmuCell to Announce Unaudited Financial Results for the Quarter Ended September 30, 2024

ImmuCell Announces Unaudited Financial Results for the Quarter Ended September 30, 2024

ImmuCell Announces Preliminary, Unaudited Sales Results for Q4 and Full Year 2024

General

ImmuCell Announces Settlement of Insurance Claim Related to Previously Disclosed Production Contamination Losses

ImmuCell to Announce Unaudited Financial Results for the Quarter and Year Ended December 31, 2024

ImmuCell Announces Unaudited Financial Results for the Quarter and Year Ended December 31, 2024

Agenus

Akari Therapeutics Plc - American Depositary Shares

Akari Therapeutics

Atara Biotherapeutics, Inc. - Common Stock

Atara Biotherapeutics

Barinthus Biotherapeutics plc - American Depositary Shares

Barinthus Biotherapeutics

Connect Biopharma Holdings Limited - American Depositary Shares

Connect Biopharma Hldgs

Precision BioSciences, Inc. - Common Stock

Precision BioSciences

Dyadic International, Inc. - Common Stock

Dyadic International

Fortress Biotech

FibroBiologics

Werewolf Therapeutics, Inc. - Common Stock

Werewolf Therapeutics

iBio

Century Therapeutics, Inc. - Common Stock

Century Therapeutics

Kala Bio

Karyopharm Therapeutics Inc. - Common Stock

Karyopharm Therapeutics

Kezar Life Sciences

Lantern Pharma

MAIA Biotechnology

OKYO Pharma

Outlook Therapeutics, Inc. - Common Stock

Outlook Therapeutics

Radiopharm Theranostics Limited - American Depositary Shares

Radiopharm Theranostics

Repare Therapeutics

Serina Therapeutics

vTv Therapeutics Inc. - Class A Common Stock

vTv Therapeutics

X4 Pharmaceuticals

Xilio Therapeutics

Comments

ImmuCell

ImmuCell (ICCC) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga